Last reviewed · How we verify
Ranibizumab Control
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye. Used for Age-related macular degeneration (wet/neovascular), Diabetic macular edema, Retinal vein occlusion.
At a glance
| Generic name | Ranibizumab Control |
|---|---|
| Sponsor | AbbVie |
| Drug class | VEGF-A inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Ranibizumab blocks VEGF-A, a key driver of pathological neovascularization and increased vascular permeability in retinal diseases. By neutralizing VEGF-A, it prevents the formation of abnormal blood vessels and reduces fluid leakage, thereby slowing or halting vision loss in conditions like age-related macular degeneration and diabetic retinopathy.
Approved indications
- Age-related macular degeneration (wet/neovascular)
- Diabetic macular edema
- Retinal vein occlusion
- Diabetic retinopathy
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
- Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD (PHASE3)
- A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (PHASE3)
- Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (PHASE3)
- Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |